Takeda reports late-breaking Phase 3 TAK-921 data in previously treated advanced gastric cancer at ESMO 2026

By Public Technologies
  • Takeda flagged late-breaking Phase 3 G-HOPE-001 data for arcotatug tavatecan (TAK-921) in previously treated advanced gastric cancer at ESMO 2026.
  • Final readout could support a Japan regulatory filing for the Claudin 18.2-targeted ADC, which remains investigational.
  • TAK-928 data in immunotherapy-resistant NSCLC and first-line NSCLC will be presented; the asset is a PD-1/alpha-biased IL-2 bispecific fusion protein.
  • Global Phase 3 MarsLight-11 is evaluating TAK-928 versus docetaxel in post-chemotherapy, post-immunotherapy squamous NSCLC; enrollment is ongoing.
  • The program will add a new sub-trial in non-squamous NSCLC, expanding the Phase 3 addressable population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220930BIZWIRE_USPR_____20260921_BW356638) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.